Literature DB >> 16902761

Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau.

Wen-Lang Lin1, Cindy Zehr, Jada Lewis, Michael Hutton, Shu-Hui Yen, Dennis W Dickson.   

Abstract

Transgenic mice expressing mutant (P301L) tau develop paresis, neurofibrillary tangles and neuronal loss in spinal motor neurons beginning at 4 to 6 months of age. Astrocytes and oligodendrocytes acquire filamentous tau inclusions at later ages. Here we report pathology in the spinal white matter of these animals. Progressive white matter pathology, detected as early as 2 months of age, was most marked in lateral and anterior columns, with sparing of posterior columns until late in the disease. Early changes in Luxol fast blue/periodic acid Schiff (LFB/PAS) and toluidine blue stained sections were vacuolation of myelin followed by accumulation of myelin figures within previous axonal tubes and finally influx of PAS-positive macrophages. Myelin debris and vacuoles were found in macrophages. At the ultrastructural level, myelinated axons showed extensive vacuolation of myelin sheaths formed by splitting of myelin lamellae at the intra-period line, while axons were atrophic and contained densely packed neurofilaments. Other axons were lost completely, resulting in collapse and phagocytosis of myelin sheaths. Also present were spheroids derived from swollen axons with thin myelin sheaths containing neurofilaments, tau filaments and degenerating organelles. Many oligodendrocytes had membrane-bound cytoplasmic bodies composed of tightly stacked lamellae capped by dense material. The vacuolar myelopathy in this model to some extent resembles that reported in acquired immune deficiency syndrome and vitamin B12 deficiency. The progressive axonal pathology is most consistent with a dying-back process caused by abnormal accumulation of tau in upstream neurons, while vacuolar myelinopathy may be a secondary manifestation of neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902761     DOI: 10.1007/s11068-006-8726-0

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  22 in total

Review 1.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

Review 2.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

3.  Age-related decline in white matter integrity in a mouse model of tauopathy: an in vivo diffusion tensor magnetic resonance imaging study.

Authors:  Naruhiko Sahara; Pablo D Perez; Wen-Lang Lin; Dennis W Dickson; Yan Ren; Huadong Zeng; Jada Lewis; Marcelo Febo
Journal:  Neurobiol Aging       Date:  2013-12-19       Impact factor: 4.673

4.  In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology.

Authors:  Francesca Caso; Maria Luisa Mandelli; Maya Henry; Benno Gesierich; Brianne M Bettcher; Jennifer Ogar; Massimo Filippi; Giancarlo Comi; Giuseppe Magnani; Manu Sidhu; John Q Trojanowski; Eric J Huang; Lea T Grinberg; Bruce L Miller; Nina Dronkers; William W Seeley; Maria Luisa Gorno-Tempini
Journal:  Neurology       Date:  2013-12-18       Impact factor: 9.910

5.  GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.

Authors:  Ismael Santa-Maria; Carmen Diaz-Ruiz; Hanna Ksiezak-Reding; Alice Chen; Lap Ho; Jun Wang; Giulio Maria Pasinetti
Journal:  Neurobiol Aging       Date:  2011-11-04       Impact factor: 4.673

6.  Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.

Authors:  Tomás L Falzone; Shermali Gunawardena; David McCleary; Gerald F Reis; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2010-09-03       Impact factor: 6.150

7.  Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.

Authors:  Ya-Fei Xu; Tania F Gendron; Yong-Jie Zhang; Wen-Lang Lin; Simon D'Alton; Hong Sheng; Monica Castanedes Casey; Jimei Tong; Joshua Knight; Xin Yu; Rosa Rademakers; Kevin Boylan; Mike Hutton; Eileen McGowan; Dennis W Dickson; Jada Lewis; Leonard Petrucelli
Journal:  J Neurosci       Date:  2010-08-11       Impact factor: 6.167

8.  Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study.

Authors:  Adam E Ludvigson; Jennifer I Luebke; Jada Lewis; Alan Peters
Journal:  Brain Struct Funct       Date:  2010-12-09       Impact factor: 3.270

9.  Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration.

Authors:  Stephanie J Adams; Richard J P Crook; Michael Deture; Suzanne J Randle; Amy E Innes; Xin Z Yu; Wen-Lang Lin; Brittany N Dugger; Melinda McBride; Mike Hutton; Dennis W Dickson; Eileen McGowan
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

10.  Structure-activity relationship of cyanine tau aggregation inhibitors.

Authors:  Edward Chang; Erin E Congdon; Nicolette S Honson; Karen E Duff; Jeff Kuret
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.